The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.
The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.
The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.
The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.
The firm, which was previously listed on the over-the-counter market, anticipates $8.5 million in net proceeds from the offering.
SingaporeGeneralHospitalwill provide blood and tissue samples for the pilot study, which is meant to establish the feasibility of VolitionRx's technology.
The study will evaluate VolitionRx's Nucleosomics platform in blood tests, adding to existing studies assessing the firm's technology at the university.
NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with the University of Oxford on a clinical study to develop biomarkers for the diagnosis of endometriosis using the firm's Nucleosomics platform.
NEW YORK (GenomeWeb News) – VolitionRx said today it has reached a deal with Active Motif to co-exclusively distribute VolitionRx's NuQ product line in Europe, the US, and Japan.
NEW YORK (GenomeWeb News) – Cancer diagnostics firm VolitionRx has raised $595,000 toward a targeted $1.5 million round, it said in a document filed with the US Securities and Exchange Commission.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.